Orbis Allan Gray Ltd trimmed its position in shares of Celgene Corporation (NASDAQ:CELG) by 96.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,863 shares of the biopharmaceutical company’s stock after selling 944,811 shares during the quarter. Orbis Allan Gray Ltd’s holdings in Celgene were worth $3,878,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of CELG. BlackRock Inc. grew its stake in shares of Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. State Street Corp grew its stake in shares of Celgene by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Celgene by 1.2% during the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after purchasing an additional 697,250 shares during the last quarter. 80.17% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (CELG) opened at $102.56 on Wednesday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market cap of $80,786.59, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 0.79 and a beta of 1.78. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17.
Several analysts have recently commented on the stock. Oppenheimer reissued an “outperform” rating and set a $175.00 price target on shares of Celgene in a research note on Wednesday, August 9th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a research note on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Piper Jaffray Companies restated a “neutral” rating and issued a $133.00 price objective on shares of Celgene in a report on Monday, October 23rd. Finally, Stifel Nicolaus cut their price objective on shares of Celgene from $155.00 to $149.00 and set a “buy” rating on the stock in a report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $139.57.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Shares Sold by Orbis Allan Gray Ltd” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/06/celgene-corporation-celg-shares-sold-by-orbis-allan-gray-ltd.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.